Showing results (761-770 of 772) with videos related to

Sort By:
Pageof 78
Science Translational Medicine|July 10, 2020
An extracorporeal bioartificial liver embedded with 3D-layered human liver progenitor-like cells relieves acute liver failure in pigsWei-Jian Li, Xue-Jing Zhu, Tian-Jie Yuan, et al.
Cell & Bioscience|October 2, 2023
CD24+LCN2+ liver progenitor cells in ductular reaction contributed to macrophage inflammatory responses in chronic liver injuryWei-Jian Huang, Bi-Jun Qiu, Xiao-Shu Qi, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging studyPaul A Goepfert, Bo Fu, Anne-Laure Chabanon, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|August 19, 2025
Transcatheter aortic valve implantation in pure aortic regurgitation: one-year outcomes of the AURORA trialFei-Cheng Yu, Xiao-Ping Peng, Jing Yao, et al.
Cell|September 17, 2013
Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathwayJames C Lee, Marion Espéli, Carl A Anderson, et al.
Eclinicalmedicine|November 8, 2023
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country studyGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
Medrxiv : the Preprint Server for Health Sciences|December 16, 2022
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein VaccineGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
The Lancet. Respiratory Medicine|September 16, 2023
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trialGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
The New England Journal of Medicine|January 25, 2018
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 InfectionStefan Zeuzem, Graham R Foster, Stanley Wang, et al.
Eclinicalmedicine|August 3, 2023
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group studyGuy de Bruyn, Joyce Wang, Annie Purvis, et al.
Pageof 78